Alfimeprase
As of the edition of 20 October 2026, Alfimeprase is an enzyme: stopped in 2008; acts on FGA, FGB and FGG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2008
- Kind
- Enzyme
- Registered trials
- 7, 2 stopped early
- Disease areas
- Heart and blood vessels; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 3 | 4 | 3 | 0 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Oruka Therapeutics | Lead sponsor of trials | 2003 to now |